CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2 (a major regulator of apoptotic cell death), selectively targets MYCN-amplified neuroblastoma through a loss of MYCN transcription and growth arrest, followed by sensitizing cells for apoptosis as a result of CDK2 inhibition (86). Here, CDK2 is linked to neuroblastoma.